Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury

• Published in: JCI insight Vol. 7; no. 21
• Main Authors: Zhong, Jianyong, Yang, Hai-Chun, Shelton, Elaine L, Matsusaka, Taiji, Clark, Amanda J, Yermalitsky, Valery, Mashhadi, Zahra, May-Zhang, Linda S, Linton, MacRae F, Fogo, Agnes B, Kirabo, Annet, Davies, Sean S, Kon, Valentina
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 08.11.2022; American Society for Clinical investigation
• Subjects: Animals; Apolipoprotein A-I - metabolism; Endothelial Cells - metabolism; Kidney - pathology; Kidney Diseases - pathology; Lipoproteins; Mice; Nephrology; Nephrology; Chronic kidney disease; Cholesterol; Lymph
• ISSN: 2379-3708; 2379-3708
• DOI: 10.1172/jci.insight.161878

Lipoprotein modification by reactive dicarbonyls, including isolevuglandin (IsoLG), produces dysfunctional particles. Kidneys participate in lipoprotein metabolism, including tubular uptake. However, the process beyond the proximal tubule is unclear, as is the effect of kidney injury on this pathway. We found that patients and animals with proteinuric injury have increased urinary apolipoprotein AI (apoAI), IsoLG, and IsoLG adduct enrichment of the urinary apoAI fraction compared with other proteins. Proteinuric mice, induced by podocyte-specific injury, showed more tubular absorption of IsoLG-apoAI and increased expression of lipoprotein transporters in proximal tubular cells compared with uninjured animals. Renal lymph reflects composition of the interstitial compartment and showed increased apoAI and IsoLG in proteinuric animals, supporting a tubular cell-interstitium-lymph pathway for renal handling of lipoproteins. IsoLG-modified apoAI was not only a marker of renal injury but also directly damaged renal cells. IsoLG-apoAI increased inflammatory cytokines in cultured tubular epithelial cells (TECs), activated lymphatic endothelial cells (LECs), and caused greater contractility of renal lymphatic vessels than unmodified apoAI. In vivo, inhibition of IsoLG by a dicarbonyl scavenger reduced both albuminuria and urinary apoAI and decreased TEC and LEC injury, lymphangiogenesis, and interstitial fibrosis. Our results indicate that IsoLG-modified apoAI is, to our knowledge, a novel pathogenic mediator and therapeutic target in kidney disease.